Lipoprotein(a) in clinical practice: A guide for the clinician

Guddeti, 2020, Lipoprotein(a) and calcific aortic valve stenosis: a systematic review, Prog Cardiovasc Dis, 63, 496, 10.1016/j.pcad.2020.06.002 Abdul-Rahman, 2023, The common pathobiology between coronary artery disease and calcific aortic stenosis: Evidence and clinical implications, Prog Cardiovasc Dis, 10.1016/j.pcad.2023.06.002 Shah, 2020, Lipoprotein (a): an update on a marker of residual risk and associated clinical manifestations, Am J Cardiol, 126, 94, 10.1016/j.amjcard.2020.03.043 Lipoprotein(a), 2009, Concentration and the risk of coronary heart disease, stroke, and nonvascular mortality, JAMA., 302, 412, 10.1001/jama.2009.1063 Yeang, 2016, Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis, Curr Opin Cardiol, 31, 440, 10.1097/HCO.0000000000000300 Miksenas, 2021, Lipoprotein(a) and cardiovascular diseases, JAMA., 326, 352, 10.1001/jama.2021.3632 Guan, 2015, Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the multi-ethnic study of atherosclerosis, Arterioscler Thromb Vasc Biol, 35, 996, 10.1161/ATVBAHA.114.304785 Reyes-Soffer, 2022, Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association, Arterioscler Thromb Vasc Biol, 42, 10.1161/ATV.0000000000000147 McLean, 1987, cDNA sequence of human apolipoprotein(a) is homologous to plasminogen, Nature., 330, 132, 10.1038/330132a0 Marcovina, 1995, Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a), Clin Chem, 41, 246, 10.1093/clinchem/41.2.246 Boffa, 2016, Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?, J Lipid Res, 57, 745, 10.1194/jlr.R060582 Tsimikas, 2017, A test in context: lipoprotein(a), J Am Coll Cardiol, 69, 692, 10.1016/j.jacc.2016.11.042 van der Valk, 2016, Oxidized phospholipids on lipoprotein(a) elicit Arterial Wall inflammation and an inflammatory monocyte response in humans, Circulation., 134, 611, 10.1161/CIRCULATIONAHA.116.020838 Hajjar, 1989, Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis, Nature., 339, 303, 10.1038/339303a0 Mach, 2020, 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk, Eur Heart J, 41, 111, 10.1093/eurheartj/ehz455 Nielsen, 1999, Atherogenecity of lipoprotein(a) and oxidized low density lipoprotein: insight from in vivo studies of arterial wall influx, degradation and efflux, Atherosclerosis., 143, 229, 10.1016/S0021-9150(99)00064-7 Boerwinkle, 1992, Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations, J Clin Invest, 90, 52, 10.1172/JCI115855 Kronenberg, 2022, Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement, Eur Heart J, 43, 3925, 10.1093/eurheartj/ehac361 Kronenberg, 2023, Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society, Atherosclerosis, 10.1016/j.atherosclerosis.2023.04.012 Gudbjartsson, 2019, Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes, J Am Coll Cardiol, 74, 2982, 10.1016/j.jacc.2019.10.019 Clarke, 2009, Genetic variants associated with Lp(a) lipoprotein level and coronary disease, N Engl J Med, 361, 2518, 10.1056/NEJMoa0902604 Pechlivanis, 2020, Association between lipoprotein(a) (Lp(a)) levels and Lp(a) genetic variants with coronary artery calcification, BMC Med Genet, 21, 62, 10.1186/s12881-020-01003-3 Thanassoulis, 2013, Genetic associations with valvular calcification and aortic stenosis, N Engl J Med, 368, 503, 10.1056/NEJMoa1109034 Arsenault, 2014, Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case–control cohort, Circ Cardiovasc Genet, 7, 304, 10.1161/CIRCGENETICS.113.000400 Li, 2022, Lipoprotein(a) and cardiovascular disease in Chinese population, JACC Asia, 2, 653, 10.1016/j.jacasi.2022.08.015 Said, 2021, Genome-wide association study and identification of a protective missense variant on lipoprotein(a) concentration: protective missense variant on lipoprotein(a) concentration—brief report, Arterioscler Thromb Vasc Biol, 41, 1792, 10.1161/ATVBAHA.120.315300 Mack, 2017, A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms, J Lipid Res, 58, 1834, 10.1194/jlr.M076232 Sultan, 2014, Review of lipid and lipoprotein(a) abnormalities in childhood arterial ischemic stroke, Int J Stroke, 9, 79, 10.1111/ijs.12136 Erqou, 2010, Apolipoprotein(a) isoforms and the risk of vascular disease, J Am Coll Cardiol, 55, 2160, 10.1016/j.jacc.2009.10.080 Boffa, 2019, Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease, Nat Rev Cardiol, 16, 305, 10.1038/s41569-018-0153-2 Capoulade, 2015, Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis, J Am Coll Cardiol, 66, 1236, 10.1016/j.jacc.2015.07.020 Dweck, 2012, Calcific Aortic Stenosis, J Am Coll Cardiol, 60, 1854, 10.1016/j.jacc.2012.02.093 Zheng, 2019, Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis, J Am Coll Cardiol, 73, 2150, 10.1016/j.jacc.2019.01.070 Bouchareb, 2015, Autotaxin derived from lipoprotein(a) and valve interstitial cells promotes inflammation and mineralization of the aortic valve, Circulation., 132, 677, 10.1161/CIRCULATIONAHA.115.016757 Cowell, 2005, A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis, N Engl J Med, 352, 2389, 10.1056/NEJMoa043876 Cao, 2016, Lipoprotein(a) levels are associated with subclinical calcific aortic valve disease in white and black individuals: the multi-ethnic study of atherosclerosis, Arterioscler Thromb Vasc Biol, 36, 1003, 10.1161/ATVBAHA.115.306683 Khera, 2014, Lipoprotein(a) concentrations, Rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating Rosuvastatin), Circulation., 129, 635, 10.1161/CIRCULATIONAHA.113.004406 Albers, 1977, Radioimmunoassay of human plasma Lp(a) lipoprotein, J Lipid Res, 18, 331, 10.1016/S0022-2275(20)41683-9 Chilazi, 2022, Quantifying the contribution of lipoprotein(a) to all apoB containing particles, J Clin Lipidol, 16, 220, 10.1016/j.jacl.2022.02.004 Virani, 2022, Global think tank on the clinical considerations and management of lipoprotein(a): the top questions and answers regarding what clinicians need to know, Prog Cardiovasc Dis, 73, 32, 10.1016/j.pcad.2022.01.002 Dati, 2004, First WHO/IFCC international reference reagent for lipoprotein(a) for immunoassay – Lp(a) SRM 2B, Clin Chem Lab Med CCLM, 42 Marcovina, 2016, Lipoprotein (a) measurements for clinical application, J Lipid Res, 57, 526, 10.1194/jlr.R061648 Marcovina, 2000, Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a), Clin Chem, 46, 1956, 10.1093/clinchem/46.12.1956 Marcovina, 2021, Development of an LC-MS/MS proposed candidate reference method for the standardization of analytical methods to measure lipoprotein(a), Clin Chem, 67, 490, 10.1093/clinchem/hvaa324 Enkhmaa, 2016, Lipoprotein (a): impact by ethnicity and environmental and medical conditions, J Lipid Res, 57, 1111, 10.1194/jlr.R051904 Sandholzer, 1991, Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups, Hum Genet, 86, 10.1007/BF00201550 Marcovina, 1996, Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans, J Lipid Res, 37, 2569, 10.1016/S0022-2275(20)37461-7 Patel, 2020, Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank, Arterioscler Thromb Vasc Biol, 10.1161/ATVBAHA.120.315291 Takahashi, 2022, Impact of lipoprotein(a) as a residual risk factor in long-term cardiovascular outcomes in patients with acute coronary syndrome treated with statins, Am J Cardiol, 168, 11, 10.1016/j.amjcard.2021.12.014 Virani, 2012, Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the atherosclerosis risk in communities (ARIC) study, Circulation., 125, 241, 10.1161/CIRCULATIONAHA.111.045120 Wilson, 2019, Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association, J Clin Lipidol, 13, 374, 10.1016/j.jacl.2019.04.010 Cook, 2018, Lipoprotein(a) and cardiovascular risk prediction among women, J Am Coll Cardiol, 72, 287, 10.1016/j.jacc.2018.04.060 Zhang, 2021, High-sensitivity C-reactive protein modifies the cardiovascular risk of lipoprotein(a), J Am Coll Cardiol, 78, 1083, 10.1016/j.jacc.2021.07.016 Langsted, 2016, High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study, Lancet Diabetes Endocrinol, 4, 577, 10.1016/S2213-8587(16)30042-0 Hulley, 1998, Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women, JAMA., 280, 605, 10.1001/jama.280.7.605 Arnett, 2019, ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines, Circulation., 140 Grundy, 2018, AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines, Circulation., 139 Piepoli, 2016, Eur Heart J, 37, 2315, 10.1093/eurheartj/ehw106 Catapano, 2016, 2016 ESC/EAS guidelines for the Management of Dyslipidaemias, Eur Heart J, 37, 2999, 10.1093/eurheartj/ehw272 Willeit, 2014, Discrimination and net reclassification of cardiovascular risk with lipoprotein(a), J Am Coll Cardiol, 64, 851, 10.1016/j.jacc.2014.03.061 Khan, 2017, Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial, Eur Heart J, 38, 1561, 10.1093/eurheartj/ehx178 Kelsey, 2023, Contemporary patterns of lipoprotein(a) testing and associated clinical care and outcomes, Am J Prev Cardiol, 14, 10.1016/j.ajpc.2023.100478 Lacaze, 2022, Aspirin for primary prevention of cardiovascular events in relation to lipoprotein(a) genotypes, J Am Coll Cardiol, 80, 1287, 10.1016/j.jacc.2022.07.027 Navarese, 2015, Effects of Proprotein convertase Subtilisin/Kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and Meta-analysis, Ann Intern Med, 163, 40, 10.7326/M14-2957 Agarwala, 2015, The role of antisense oligonucleotide therapy in patients with familial hypercholesterolemia: risks, benefits, and management recommendations, Curr Atheroscler Rep, 17, 467, 10.1007/s11883-014-0467-4 Jia, 2021, Lipid-lowering biotechnological drugs: from monoclonal antibodies to antisense therapies—a clinical perspective, Cardiovasc Drugs Ther, 35, 1269, 10.1007/s10557-020-07082-x Sahebkar, 2016, Effect of extended-release niacin on plasma lipoprotein(a) levels: a systematic review and meta-analysis of randomized placebo-controlled trials, Metabolism., 65, 1664, 10.1016/j.metabol.2016.08.007 Anderson, 2014, Safety profile of extended-release niacin in the AIM-HIGH trial, N Engl J Med, 371, 288, 10.1056/NEJMc1311039 Willeit, 2018, Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials, Lancet, 392, 1311, 10.1016/S0140-6736(18)31652-0 Tsimikas, 2020, Statin therapy increases lipoprotein(a) levels, Eur Heart J, 41, 2275, 10.1093/eurheartj/ehz310 Schwartz, 2021, Lipoprotein(a) and benefit of PCSK9 inhibition in patients with nominally controlled LDL cholesterol, J Am Coll Cardiol, 78, 421, 10.1016/j.jacc.2021.04.102 Arai, 2012, Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia, J Lipid Res, 53, 1670, 10.1194/jlr.P027235 Rosada, 2014, Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events?: lipid apheresis in LP(a) patients, Artif Organs, 38, 135, 10.1111/aor.12135 Roeseler, 2016, Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease: prospective 5 years of follow-up and apolipoprotein(a) characterization, Arterioscler Thromb Vasc Biol, 36, 2019, 10.1161/ATVBAHA.116.307983 Viney, 2016, Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials, Lancet, 388, 2239, 10.1016/S0140-6736(16)31009-1 Moriarty, 2015, Lipoprotein apheresis, Cardiol Clin, 33, 197, 10.1016/j.ccl.2015.02.002 Shlipak, 2000, Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause, JAMA., 283, 1845, 10.1001/jama.283.14.1845 Duell, 2016, Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia, J Clin Lipidol, 10, 1011, 10.1016/j.jacl.2016.04.013 Raal, 2014, Reduction in lipoprotein(a) with PCSK9 monoclonal antibody Evolocumab (AMG 145), J Am Coll Cardiol, 63, 1278, 10.1016/j.jacc.2014.01.006 Kaiser, 2022, Association of Lipoprotein(a) with atherosclerotic plaque progression, J Am Coll Cardiol, 79, 223, 10.1016/j.jacc.2021.10.044 Cannon, 2015, Ezetimibe added to statin therapy after acute coronary syndromes, N Engl J Med, 372, 2387, 10.1056/NEJMoa1410489 Albers, 2013, Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes, J Am Coll Cardiol, 62, 1575, 10.1016/j.jacc.2013.06.051 Nestel, 2013, Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease, Arterioscler Thromb Vasc Biol, 33, 2902, 10.1161/ATVBAHA.113.302479 Paré, 2019, Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups, Circulation., 139, 1472, 10.1161/CIRCULATIONAHA.118.034311